Fisseha Makda, Chen Ping, Brandt Brenda, Kijek Todd, Moran Elizabeth, Zollinger Wendell
The Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, Maryland 20910-7500, USA.
Infect Immun. 2005 Jul;73(7):4070-80. doi: 10.1128/IAI.73.7.4070-4080.2005.
Native outer membrane vesicles (NOMV) of Neisseria meningitidis consist of intact outer membrane and contain outer membrane proteins (OMP) and lipooligosaccharides (LOS) in their natural conformation and membrane environment. NOMV have been safely used intranasally in P1 studies with encouraging results, but they are too toxic for parenteral vaccination. We now report the preparation and characterization of lpxL mutants that express LOS with reduced toxicity, and the evaluation of the potential of NOMV from these strains for use as a parenteral vaccine. A series of deletion mutants were prepared with knockouts of one or more of the lpxL1, lpxL2, or synX genes. The deltalpxL2 mutants had a reduced growth rate, reduced level of LOS expression, and increased sensitivity to surfactants. In addition, deltasynX deltalpxL2 double mutants had reduced viability in stationary phase. The deltalpxL1 deltalpxL2 double mutant behaved essentially the same as the deltalpxL2 single mutant. LOS from both lpxL mutant strains exhibited altered migration on polyacrylamide gels. The LOS of deltalpxL2 mutants of L3,7 strains were fully sialylated. NOMV prepared from lpxL2 mutants was about 200-fold less active than wild-type NOMV in rabbit pyrogen tests and in tumor necrosis factor alpha release assays. Bactericidal titers induced in animals by deltalpxL2 mutant NOMV were lower than those induced by deltalpxL1 or wild-type NOMV. However, immunogenicity could be largely restored by use of an adjuvant. These results provide evidence that NOMV from deltalpxL2 mutant strains will be safe and immunogenic in humans when given parenterally.
脑膜炎奈瑟菌的天然外膜囊泡(NOMV)由完整的外膜组成,在其天然构象和膜环境中含有外膜蛋白(OMP)和脂寡糖(LOS)。NOMV已在P1研究中经鼻安全使用,结果令人鼓舞,但它们对肠胃外疫苗接种毒性太大。我们现在报告表达毒性降低的LOS的lpxL突变体的制备和表征,以及对来自这些菌株的NOMV用作肠胃外疫苗的潜力的评估。制备了一系列缺失一个或多个lpxL1、lpxL2或synX基因的缺失突变体。deltalpxL2突变体生长速率降低,LOS表达水平降低,对表面活性剂的敏感性增加。此外,deltasynX deltalpxL2双突变体在稳定期的活力降低。deltalpxL1 deltalpxL2双突变体的表现与deltalpxL2单突变体基本相同。来自两种lpxL突变体菌株的LOS在聚丙烯酰胺凝胶上迁移发生改变。L3,7菌株的deltalpxL2突变体的LOS完全唾液酸化。在兔热原试验和肿瘤坏死因子α释放试验中,由lpxL2突变体制备的NOMV的活性比野生型NOMV低约200倍。deltalpxL2突变体NOMV在动物中诱导的杀菌效价低于deltalpxL1或野生型NOMV诱导的效价。然而,使用佐剂可在很大程度上恢复免疫原性。这些结果提供了证据,表明来自deltalpxL2突变体菌株的NOMV经肠胃外给药时在人类中是安全且具有免疫原性的。